2383 results about "Combination therapy" patented technology

Provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of an immunomodulator inhibitor and a compound of Formula (II).

Provided herein are methods of treating cancer by administering a combination therapy comprising a KRAS G12D inhibitor and a PD-1 inhibitor or a PD-L1 inhibitor.

Provided herein are methods of treating cancer by administering a combination therapy comprising a KRAS G12D inhibitor and an EGFR inhibitor.

The present invention provides methods of treating a cancer patient with an inhibitor of KRAS and an anti-CCR8 antibody. These methods are useful for treating a number of cancers, including pancreatic, colorectal, and lung cancers.

The present disclosure features a combination therapy useful for the treatment of solid tumors.

The present invention provides combination therapy that includes an KRASG12C inhibitor, such asor a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

The invention discloses application of an anti-CD20 antibody drug conjugate or a drug combination thereof in preparation of a drug for treating diffuse large B-cell lymphoma. The drug combination comprises the anti-CD20 antibody drug conjugate, gemcitabine and oxaliplatin, the anti-CD20 antibody drug conjugate or the drug combination therapy containing the anti-CD20 antibody drug conjugate has a better curative effect compared with the existing clinical second-line standard therapy.

The invention provides a method of treating a tumor in a human gastric cancer or gastroesophageal junction cancer patient.

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.

The present application discloses combinations for treating estrogen receptor-positive and HER2-positive breast cancer patients. The combinations comprise pertuzumab and trastuzumab (e.g. a fixed dose combination of pertuzumab and trastuzumab, PH FDC) plus giredestrant. In one embodiment, the combination further includes a CDK4 / 6 inhibitor, such as abemaciclib or palbociclib.

The invention provides an asymmetric drug interaction prediction method based on a diffusion diagram attention network, and relates to the technical field of drug interaction prediction.The method comprises the steps that a directed graph network is constructed by using chemical structure features of drug molecules, and features are extracted from drug applying and receiving perspectives through a two-way diagram attention network; therefore, the asymmetry between the drugs is effectively represented. Furthermore, a diffusion model is introduced to carry out noise injection and de-noising processing on a graph structure, so that the adaptability of the model to sparse data and the robustness of feature extraction are remarkably enhanced. Finally, multi-modal features are fused through a deep neural network, and high-precision prediction of drug interaction is realized. Compared with the prior art, the method has the advantages that the prediction accuracy exceeds that of the prior art, the dependence on labeled data is greatly reduced, the feasibility and generalization ability of the model in practical application are greatly improved, and a new technical path is provided for safety evaluation and precise medical research of drug combination therapy.

Provided herein are novel anti-CD20 x anti-CD28 antibodies and methods of using such antibodies for the treatment of B-cell malignancies. Subject anti-CD20 x anti-CD28 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and CD20 on tumor cells. Thus, such antibodies enhance anti-tumor activity at tumor sites. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-CD20 x anti-CD79b antibodies) for the treatment of B-cell malignancies.

The present application provides methods of treating cancer using a combination of a DGK inhibitor and an inhibitor of PD-1 and / or PD-L1.

Disclosed herein is use of a combination of Compound (A) (azenosertib), or a pharmaceutically acceptable salt thereof, and a KRAS G12C inhibitor, such as sotorasib or adagrasib, or a pharmaceutically acceptable salt thereof, for treating a disease or condition, such as a colorectal, pancreatic and / or non-small cell lung cancer.

The invention provides combination therapies comprising disease modifying anti-rheumatic drugs and mitochondrial complex I modulator (MCIM) compounds, which find utility in the medical field of inflammatory and progressive disorders, for example autoimmune diseases such as arthritis.

Described herein, in part, are methods of treating cancer in patients in need thereof, comprising administering to the patient a VPS34 inhibitor and one or more additional therapeutic agents, such as a STING agonist.

The invention provides a coordination nano assembly of chiral cyclopeptide and manganese ions as well as a preparation method and application of the coordination nano assembly. According to the method, a manganese superoxide dismutase protein structural domain and a unique tumor microenvironment of melanoma high tyrosinase are combined, and polypeptide sequences L-YD-hL-DD-h, L-YL-HL-DL-H and D-yD-hD-dD-h with different chirality are designed for the first time; the chirality of the polypeptide is regulated and controlled, the in-vivo circulation stability and the cell entry efficiency of the nano assembly are improved, the coordination self-assembly of manganese and different chiral cyclopeptides is realized, and the in-situ oxidation of an in-vivo tumor microenvironment is simulated for photo-thermal therapy and cell membrane coating. The method disclosed by the invention is simple, mild in experimental condition and easy to operate, the prepared cell membrane coated nano assembly not only has long circulation stability and high cell entry efficiency, but also can realize mild photo-thermal therapy through in-situ oxidation, releases manganese ions to activate a CGAS-STING pathway for immunotherapy of tumors, and has a wide application prospect. The potential application value is realized in the field of combined treatment of tumors.

Provided herein is, among other things, is a method of treating cancer using an improved intermittent dosing regimen for Azenosertib, or a pharmaceutically acceptable salt thereof, administration to achieve a highly efficacious, safe and tolerable dosing regimen to treat many different types of cancers. In one aspect, the method of treating cancer comprises administering a daily dose of Azenosertib, or a pharmaceutically acceptable salt thereof, (e.g., greater than about 350 mg) in accordance with an improved intermittent dosing cycle, wherein the intermittent dosing cycle comprises one or more dosing weeks with each dosing week comprising between about 2-7 consecutive dosing days and between about 1-7 days without dosing. In some embodiments, the intermittent dosing cycle is repeated wherein the dosing weeks are separated by a break of one, two or more weeks. In some aspects, Azenosertib, or a pharmaceutically acceptable salt thereof, is administered as a combination therapy.

Provided are methods for combination treatment of a cancer using an antibody-drug conjugate (ADC) targeting CEACAM5 and an anti-PD-1 antibody or anti-PD-L1 antibody, optionally together with a platinum-containing agent such as cisplatin or carboplatin with or without pemetrexed. In certain embodiments the ADC is tusamitamab ravtansine. In certain embodiments the anti-PD-1 antibody is pembrolizumab. In certain embodiments, the cancer is nonsquamous non-small cell lung cancer (NSQ NSCLC). In certain embodiments, the cancer is advanced or metastatic NSQ NSCLC.

The invention provides a method of treating a colorectal carcinoma with a combination of an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody. In some aspects, the combination comprises 480 mg of each antibody such as, for example, 480 mg of an anti-LAG-3 antibody (e.g, relatlimab) and 480 mg of an anti-PD-1 antibody (e.g, nivolumab). In some aspects, the colorectal carcinoma is unresectable, advanced, or metastatic, including, for example, microsatellite stable or high microsatellite instable colorectal carcinoma.

Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.

The invention discloses poplar and phellinus igniarius polysaccharide SVP-1 as well as a preparation method and application thereof, and belongs to the field of biological medicines. The poplar phellinus igniarius polysaccharide SVP-1 provided by the invention has remarkable anti-tumor activity, and can effectively inhibit proliferation, invasion and migration of tumor cells so as to block malignant progression of tumors. The structure is clear, the preparation method is controllable, the stability and biological activity of polysaccharide components are ensured, and a reliable basis is provided for development of antitumor drugs. When the traditional Chinese medicine composition is used together with radiotherapy and chemotherapy medicines, a synergistic effect can be achieved, the sensitivity of tumors to treatment can be improved, the toxic and side effects of radiotherapy and chemotherapy can be relieved, and the effects of reducing toxicity and increasing efficiency are achieved. According to the combined treatment strategy, the curative effect of the existing tumor therapy can be remarkably improved, meanwhile, adverse reactions are reduced, and a new optimization scheme is provided for clinical tumor treatment.

Described herein is a composition or a kit comprising a therapeutically effective amount of a TEAD inhibitor and a therapeutically effective amount of other types of inhibitors that are useful for treating cancer, including relapsed or refractory cancer. Also, described herein is a method of treating cancer in a patient in need thereof, including administering to the patient a therapeutically effective amount of a TEAD inhibitor and a therapeutically effective amount of other types of inhibitors. Specific cancer, such as relapsed or refractory cancers, includes those that are mediated by YAP / TAZ or those that are modulated by the interaction between YAP / TAZ and TEAD.

The present invention relates to combination therapy with (a) a mutant IDH inhibitor having the Formula I and (b) one or more of an antimetabolite agent, a hypomethylating agent, and a mutant Flt3 (Flt3) inhibitor, for the treatment of cancer.

A system and method are herein disclosed. The system and method use a generative AI agent to analyze and identify synergistic blends of natural compounds for combination therapies by leveraging an array of specialized modes to access data from a multitude of sources including patient medical history (including test results, drug history, and imaging) to improve the efficacy of compounds, including traditional medicine, in line with combination therapy principles, aimed at: enhanced efficacy, decreased toxicity, improved dosage, and reduced drug resistance. In this way, the generative AI agent determines cross-therapeutic similarities and / or dissimilarities between pharmaceutical, naturopathic, homeopathic, and nutraceutical compounds along a plurality of compound property vectors such as efficiency, efficacy, toxicity, effects, side-effects, chemistry, pharmacology, pharmacokinetics, mechanisms of action, and pharmacodynamics, thereby enabling the proposition of cross-disciplinary and transdisciplinary therapeutic analyses and the identification of synergistic effects in combination therapies.

This application relates the use of a combination of a membrane-associated tyrosine and threonine- specific CDC2-inhibitory kinase (Myt1) inhibitor with a Weel inhibitors in treating cancer or inducing cell death. The synergistic effect of the combination results in a subtherapeutic dose or a reduced dosing schedule of the Myt1 inhibitor, the Wee1 inhibitor, or both relative to a monotherapy of either the Myt1 inhibitor or the Wee1 inhibitor in isolation.

Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.

The present disclosure provides a pharmaceutical composition for the prevention or treatment of neurodegenerative disorders comprising a phosphodiesterase 5 inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist or a dipeptidyl peptidase IV (DPP-4) inhibitor as active ingredients. The phosphodiesterase 5 inhibitor is selected from mirodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, and pharmaceutically acceptable salts, solvates and hydrates thereof. The GLP-1 receptor agonist is selected from semaglutide, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, tirzepatide, cotadutide, and taspoglutide. The DPP-4 inhibitor is selected from sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, teneligliptin, alogliptin, evogliptin, and anagliptin. The combination exhibits synergistic effects in reducing intracellular Aβ42, IL1β, and TNFα levels compared to the individual compounds alone.

Provided is a combination therapy for an antitumor agent that exhibits a high antitumor effect using a pyridone carboxylic acid derivative.　An antitumor agent characterized by being administered in combination with other antitumor agents, and comprising, as an active ingredient, a compound represented by the formula (1) (in the formula, the wavy line represents the steric configuration being the R configuration or the S configuration) or a salt thereof, wherein the other antitumor agents are one or more types selected from cytarabine, venetoclax, azacitidine, gilteritinib, birabresib, vorinostat, GSK126, MK-8776, AZD7762, rabusertib, dabrafenib, vemurafenib, olaparib, adavosertib, alisertib, decitabine, midostaurin, and AZD5991.

Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and / or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.